Cancer sites (ICD-10 code) | Baseline SIRs (95% CI)* | RRs (95% CI) by cumulative badge dose categories (mSv) | P trend | |||
<1 | 1–5 | 5–20 | ≥20 | |||
All cancers combined (C00-C96) | 1.00 (0.95 to 1.05) | 1.0 (ref) | 0.96 (0.88 to 1.05) | 0.97 (0.88 to 1.06) | 0.94 (0.86 to 1.04) | 0.753 |
Cases | 1382 | 776 | 620 | 614 | ||
Solid cancers (C00-C81) | 0.99 (0.94 to 1.05) | 1.0 (ref) | 0.95 (0.87 to 1.04) | 0.97 (0.88 to 1.06) | 0.94 (0.85 to 1.04) | 0.779 |
Cases | 1317 | 734 | 588 | 581 | ||
Solid cancers other than thyroid | 0.88 (0.83 to 0.95) | 1.0 (ref) | 0.89 (0.79 to 0.99) | 0.91 (0.81 to 1.03) | 0.99 (0.89 to 1.11) | 0.511 |
Cases | 850 | 474 | 406 | 504 | ||
Solid cancers other than thyroid and lung | 0.91 (0.85 to 0.97) | 1.0 (ref) | 0.89 (0.79 to 1.00) | 0.93 (0.82 to 1.05) | 1.02 (0.91 to 1.14) | 0.537 |
Cases | 794 | 443 | 382 | 456 | ||
All-haematopoietic cancers (C81-C96) | 1.20 (0.94 to 1.53) | 1.0 (ref) | 1.04 (0.70 to 1.53) | 0.94 (0.62 to 1.44) | 0.99 (0.65 to 1.50) | 0.788 |
Cases | 65 | 42 | 32 | 33 | ||
Stomach (C16) | 0.71 (0.59 to 0.84) | 1.0 (ref) | 1.03 (0.78 to 1.35) | 0.94 (0.70 to 1.26) | 0.93 (0.70 to 1.23) | 0.288 |
Cases | 125 | 88 | 70 | 83 | ||
Colorectal (C18-C20) | 0.98 (0.83 to 1.17) | 1.0 (ref) | 0.85 (0.64 to 1.13) | 0.85 (0.63 to 1.15) | 1.01 (0.77 to 1.33) | 0.482 |
Cases | 130 | 73 | 62 | 86 | ||
Liver (C22) | 0.54 (0.42 to 0.71) | 1.0 (ref) | 0.92 (0.61 to 1.38) | 0.95 (0.63 to 1.45) | 1.38 (0.96 to 1.97) | 0.484 |
Cases | 56 | 39 | 36 | 63 | ||
Pancreas (C25) | 1.32 (0.90 to 1.92) | 1.0 (ref) | 0.57 (0.27 to 1.17) | 0.64 (0.31 to 1.32) | 0.67 (0.35 to 1.27) | 0.795 |
Cases | 27 | 10 | 10 | 14 | ||
Lung (C33-C34) | 0.64 (0.49 to 0.83) | 1.0 (ref) | 0.87 (0.56 to 1.36) | 0.73 (0.46 to 1.19) | 0.92 (0.63 to 1.36) | 0.518 |
Cases | 56 | 31 | 24 | 48 | ||
Non-melanoma skin (C44) | 0.69 (0.37 to 1.28) | 1.0 (ref) | 1.66 (0.69 to 4.00) | 1.79 (0.73 to 4.41) | 1.49 (0.61 to 3.67) | 0.785 |
Cases | 10 | 10 | 9 | 9 | ||
Female breast (C50) | 1.11 (0.95 to 1.30) | 1.0 (ref) | 1.00 (0.75 to 1.34) | 1.00 (0.71 to 1.41) | 1.01 (0.53 to 1.91) | 0.799 |
Cases | 155 | 98 | 53 | 20 | ||
Prostate (C61) | 1.76 (1.37 to 2.25) | 1.0 (ref) | 0.61 (0.38 to 1.00) | 0.56 (0.33 to 0.93) | 0.92 (0.64 to 1.32) | 0.756 |
Cases | 62 | 22 | 19 | 53 | ||
Kidney (C64) | 1.57 (1.19 to 2.09) | 1.0 (ref) | 0.70 (0.42 to 1.16) | 1.02 (0.64 to 1.64) | 0.92 (0.57 to 1.50) | 0.425 |
Cases | 48 | 22 | 27 | 25 | ||
Bladder (C67) | 0.98 (0.61 to 1.57) | 1.0 (ref) | 0.71 (0.31 to 1.64) | 1.84 (0.96 to 3.54) | 1.15 (0.59 to 2.23) | 0.535 |
Cases | 17 | 8 | 19 | 18 | ||
Brain and CNS (C70-72) | 1.45 (0.94 to 2.24) | 1.0 (ref) | 0.48 (0.19 to 1.20) | 1.07 (0.51 to 2.24) | 0.66 (0.26 to 1.63) | 0.860 |
Cases | 20 | 6 | 11 | 6 | ||
Thyroid (C73) | 1.26 (1.15 to 1.38) | 1.0 (ref) | 1.18 (1.01 to 1.37) | 1.29 (1.09 to 1.53) | 1.18 (0.93 to 1.50) | 0.990 |
Cases | 467 | 260 | 182 | 77 | ||
NHL (C82-C85, C96) | 0.79 (0.51 to 1.22) | 1.0 (ref) | 1.27 (0.66 to 2.46) | 1.14 (0.56 to 2.34) | 1.24 (0.61 to 2.48) | 0.953 |
Cases | 20 | 16 | 12 | 13 | ||
Leukaemia (C91-C95) | 1.23 (0.83 to 1.80) | 1.0 (ref) | 1.00 (0.54 to 1.86) | 0.37 (0.14 to 0.97) | 0.90 (0.44 to 1.81) | 0.863 |
Cases | 26 | 16 | 5 | 11 |
*SIR for the <1 mSv dose category.
CNS, central nervous system; ICD-10, International Classification of Diseases and Related Health Problems, 10th Revision; NHL, non-Hodgkin’s lymphoma; RR, relative risk.